HOME >> BIOLOGY >> NEWS
Award winning researchers reveal potential new role for Glivec

Geneva, Switzerland: Imatinib or Glivec as it also known looks as if it may become an effective treatment for yet another type of cancer.

Consultant medical oncologist Dr. Grant McArthur told a news briefing today (Wednesday 29 September) that a Phase II study by an international team has shown that the drug is active against a rare type of cancer called dermatofibrosarcoma protuberans (DFSP) a malignant tumour that occurs in the second layer of the skin (the dermis)[1].

He said that complete control of the disease was achieved in eight out of 10 patients in a Phase II trial either through imatinib alone or imatinib plus surgery. The research team are preparing to present their findings to regulatory bodies for approval for imatinib's use as a treatment for unresectable DFSP when it exhibits a particular genetic profile.

The study, presented at the EORTC-NCI-AACR[2] Symposium on Molecular Targets and Cancer Therapeutics in Geneva, was selected as a proffered paper by the scientific board of the EORTC-NCI-AACR and also won an award from the Fondation Nelia et Amadeo Barletta (FNAB)[3], a foundation devoted to supporting worldwide translational research aimed at individualising therapeutics. The award is being presented today to Dr. McArthur, the lead researcher, by Professor Esteban Cvitkovic, president of the foundation's scientific board.

Dr McArthur, who is head of the Molecular Oncology and Translational Research Laboratories at the Peter McCallum Cancer Centre in Melbourne, Australia, said that the decision to try imatinib in the treatment of DFSP arose from pioneering research from another team published in 1997[4] . This had shown that a gene called the platelet-derived growth factor receptor B (PDGFB) was re-arranged in DFSP, involving a translocation between chromosomes 17 and 22.

"It was intuitive to try imatinib in the disease because this translocation results in over expression of PDGFB and imatinib is an inhi
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
41-227-612-205
European Organisation for Research and Treatment of Cancer
29-Sep-2004


Page: 1 2 3

Related biology news :

1. Gladstone investigator Mike McCune wins prestigious NIH Directors Pioneer Award
2. UT Southwestern biochemist honored with NIH Directors Pioneer Award
3. UMaine anthropologist wins Solon T. Kimball Award
4. Secretary of Energy announces seven E.O. Lawrence Award Winners
5. Martin Saunders to receive the James Flack Norris Award
6. Berkeley Lab soil scientist Margaret Torn receives Presidential Early Career Award
7. NJIT professor receives Presidential Award for breakthrough research with adult stem cells
8. Second call for proposals for the European Young Investigator Award
9. Virginia Tech professor honored with DeLaval Award
10. Institute for OneWorld Health nominated for the 2004 World Technology Awards
11. EURYI Award given for the first time to 25 young European researchers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/26/2019)... , ... October 24, 2019 , ... World Cord Blood ... parents, doctors, nurses, and midwives to learn about the current and future uses of ... Cord blood is now being used to treat and cure over 80 different life-threatening ...
(Date:10/26/2019)... ... October 25, 2019 , ... The ... in La Plata, MD. Orofacial myofunctional disorders (OMDs) are abnormal movement patterns of ... speaks. This can include anything from difficulty swallowing and limited tongue movement to ...
(Date:10/22/2019)... ... October 22, 2019 , ... Greenberg Traurig, LLP’s global ... Deal Making in the Life Sciences Sector,” with German biotech strategy consulting firm, Catenion. ... at Greenberg Traurig’s Tokyo office . , Speakers from Greenberg Traurig and Catenion ...
Breaking Biology News(10 mins):
(Date:11/2/2019)... TORONTO (PRWEB) , ... October 31, 2019 , ... ... at Adaptive Biotechnologies in a live webinar on Friday, ... application in immuno-oncology. , Immunosequencing, the science of profiling T-cell receptors (TCRs) ...
(Date:10/30/2019)... ... , ... While using cold plasma to kill cancer cells isn’t an entirely ... Mines & Technology are exploring new ways to regulate cold plasma technology to ... the technique would prove to be a drug-free, minimally invasive cancer treatment that would ...
(Date:10/29/2019)... ... ... CaroGen Corporation , a biotechnology company, today announced three distinguished additions ... Wands, MD, of Brown University , Dr. Steve Projan, PhD, FAAM, formerly ... of Wayne State University, formerly a professor at Yale University School of Medicine ...
(Date:10/29/2019)... Mass. (PRWEB) , ... October 29, 2019 , ... ... spectral signature of the skin*. Using Silios CMS-C multispectral imagers , researchers ... new approach can replace identification based on retinal imaging, face recognition, fingerprints and ...
Breaking Biology Technology:
Cached News: